Loading stock data…
Xenetic Biosciences (XBIO)
$2.85-0.16 (-5.16%)
Market ClosedLast close Jun 29
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Xenetic Biosciences, Inc. in the Healthcare sector is trading at $2.85 with a market capitalization of $7M. The stock is currently near its 52-week low of $1.90, remaining 3.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $806,923↑ | $766,296↓ | $1.03M↑ | $589,897↓ | $593,261 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$502,117↑ | -$623,027↓ | -$544,734↑ | -$724,412↑ | -$942,409 |
| Net Income | -$456,382↑ | -$579,076↓ | -$509,940↑ | -$688,703↑ | -$903,141 |
Peer Comparison
JNJUNHPFE
Fundamentals
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.14%
Volume
Today's trading volume
2,889
Recent News
Xenetic Biosciences: Q4 Earnings Snapshot
FRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Thursday reported a loss of $579,000 in its fourth quarter.
Xenetic Biosciences: Q3 Earnings Snapshot
FRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Wednesday reported a loss of $510,000 in its third quarter.
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +30.77% and +1.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences: Q2 Earnings Snapshot
FRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Tuesday reported a loss of $689,000 in its second quarter.